This technology utilizes MC1, a low-molecular-weight ginsenoside derived from the deglycosylation of ginseng saponin, as an active ingredient in pharmaceutical and food compositions for the prevention and treatment of fatty liver, hyperinsulinemia, hyperglycemia, diabetes, and insulin resistance. MC1 is defined as a compound with a specific structure where arabinose and glucose are bound to a protopanaxadiol backbone.
While obesity and metabolic diseases are rapidly increasing due to Westernized diets, lack of exercise, and an aging population, developing clear treatments has been challenging because these conditions involve complex, intertwined causes such as glucose and lipid metabolism disorders.
This technology focuses on the effect of MC1 in inhibiting reactive oxygen species in cardiomyocytes and increasing the survival rate of cardiomyocytes and vascular endothelial cells. It is designed to utilize MC1 isolated from ginseng extracts—such as fresh, red, or white ginseng—or through synthetic or commercial sources. It can be applied to drug candidates for diabetes and insulin resistance, functional red ginseng foods for blood sugar management, and health supplements for fatty liver, allowing for the design of metabolic disease products that target blood sugar, insulin, and liver fat issues simultaneously using a single ginseng-derived low-molecular-weight component.
WO2020-032448A1
